NEW YORK (GenomeWeb) – Members of the Children's Oncology Group have generated evidence supporting the notion that a five-gene expression signature can help predict survival patterns for pediatric rhabdomyosarcoma cases lacking a fusion between the PAX and FOXO1 genes.

Researchers from the US, Switzerland, and the UK set out to test the prognostic potential of the previously described signature in 57 children who appeared to fall in an intermediate risk group. Their findings are slated to appear today in Clinical Cancer Research.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Osamu Shimomura, who won the 2008 Nobel Prize in Chemistry for his work on green fluorescent protein, has died.

The US National Institutes of Health has developed guidelines to gauge whether frail chimpanzees are healthy enough to be moved to a retirement sanctuary.

In PLOS this week: analytical approach for finding new genetic associations, analysis of Streptococcus pyogenes-infecting viruses, and more.

Stat News reports that the head of IBM Watson Health is leaving her post.

Oct
25
Sponsored by
Roche

This webinar will detail a comprehensive strategy that a lab has put in place to evaluate  NGS oncology assays for genomic tumor profiling of plasma and tissue samples.  

Nov
05
Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

Nov
07
Sponsored by
Qiagen

This webinar will provide a first-hand look at how a leading pathology lab implemented a next-generation sequencing panel to capture comprehensive molecular tumor profiles.

Nov
27
Sponsored by
Genialis & Roche

While next-generation sequencing (NGS) has driven recent advances in precision oncology research, it often falls short when identifying the molecular mechanisms underlying many malignancies. As a result, alternative NGS-based approaches are needed to identify oncogenic drivers and potential drug targets.